DE69428905D1 - Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels - Google Patents

Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels

Info

Publication number
DE69428905D1
DE69428905D1 DE69428905T DE69428905T DE69428905D1 DE 69428905 D1 DE69428905 D1 DE 69428905D1 DE 69428905 T DE69428905 T DE 69428905T DE 69428905 T DE69428905 T DE 69428905T DE 69428905 D1 DE69428905 D1 DE 69428905D1
Authority
DE
Germany
Prior art keywords
factor viii
therapeutic agent
treating
defect
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69428905T
Other languages
English (en)
Other versions
DE69428905T2 (de
Inventor
Joseph Edward Curtis
Sam Leland Helgerson
Roger L Lundblad
Shu-Len Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of DE69428905D1 publication Critical patent/DE69428905D1/de
Publication of DE69428905T2 publication Critical patent/DE69428905T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69428905T 1993-09-13 1994-08-26 Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels Expired - Fee Related DE69428905T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/120,894 US5576291A (en) 1993-09-13 1993-09-13 Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
PCT/US1994/009613 WO1995007713A1 (en) 1993-09-13 1994-08-26 Activated factor viii as a therapeutic agent and method of treating factor viii deficiency

Publications (2)

Publication Number Publication Date
DE69428905D1 true DE69428905D1 (de) 2001-12-06
DE69428905T2 DE69428905T2 (de) 2002-05-29

Family

ID=22393146

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428905T Expired - Fee Related DE69428905T2 (de) 1993-09-13 1994-08-26 Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels

Country Status (10)

Country Link
US (1) US5576291A (de)
EP (1) EP0719154B1 (de)
JP (1) JPH09502714A (de)
AT (1) ATE207759T1 (de)
AU (1) AU686661B2 (de)
CA (1) CA2168332A1 (de)
DE (1) DE69428905T2 (de)
DK (1) DK0719154T3 (de)
ES (1) ES2166783T3 (de)
WO (1) WO1995007713A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
NZ516400A (en) * 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
JP4643783B2 (ja) * 1999-12-24 2011-03-02 一般財団法人化学及血清療法研究所 フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1458408B1 (de) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Flüssige zusammensetzung aus faktor vii polypeptiden
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP1517698B2 (de) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISIERTE FESTE ZUSAMMENSETZUNGEN VON FAKTOR VIIa POLYPEPTIDEN
JP2006524195A (ja) * 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
EP1656158B1 (de) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Flüssige, wässrige pharmazeutische zusammensetzung von faktor-vii-polypeptiden
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
EP2298287B1 (de) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
DE602006018622D1 (de) * 2005-06-30 2011-01-13 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101678066B (zh) 2007-04-26 2014-09-24 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
RU2531493C2 (ru) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Рекомбинантный фактор viii, обладающий повышенной стабильностью
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
EP2393828B1 (de) 2009-02-03 2016-10-12 Amunix Operating Inc. Verlängerte rekombinante polypeptide und zusammensetzungen damit
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2016179547A1 (en) * 2015-05-06 2016-11-10 Evans Matthew Stephen Development of novel automated screening method for detection of fviii inhibitors
EP3331608A4 (de) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. Faktor-ix-fusionsproteine und verfahren zur herstellung und verwendung davon

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US5101016A (en) * 1983-03-31 1992-03-31 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies to them
US4857635A (en) * 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
CA1341506C (en) * 1983-03-31 2006-06-06 Theodore S. Zimmerman Factor viii coagulant polypeptides and monoclonal antibodies to them
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (de) * 1985-04-12 1992-02-26 Genetics Institute, Inc. Neue prokoagulierungsproteine
US4769336A (en) * 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
US5149687A (en) * 1991-04-01 1992-09-22 United Technologies Corporation Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa

Also Published As

Publication number Publication date
US5576291A (en) 1996-11-19
AU686661B2 (en) 1998-02-12
AU7638094A (en) 1995-04-03
EP0719154B1 (de) 2001-10-31
DE69428905T2 (de) 2002-05-29
ATE207759T1 (de) 2001-11-15
WO1995007713A1 (en) 1995-03-23
JPH09502714A (ja) 1997-03-18
DK0719154T3 (da) 2001-11-26
ES2166783T3 (es) 2002-05-01
EP0719154A1 (de) 1996-07-03
CA2168332A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
DE69428905T2 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60028573D1 (de) Behandlung und zusammensetzungen zur erzielung eines hautalterungsschutzes durch corneum protease aktivatoren
DE59306276D1 (de) Verfahren und anordnung zur therapie von gewebe mit ultraschall
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69807115T2 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE119147T1 (de) Verbindungen und zusammensetzungen zur anwendung bei methoden zur behandlung und prophylaxe von pneumocystis carinii pneumonia und anderen krankheiten.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69721824D1 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
DE69626311T2 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
DE69523506D1 (de) Verwendung eines Enzyms zur Herstellung eines Mittels für die Behandlung und/oder Prophylaxe von Coccidiose
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
ATE219372T1 (de) Verfahren zur behandlung von blutungsstorungen
DE60042171D1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE69403372T2 (de) Poliermittel und Verfahren zur Behandlung von calciumcarbonathaltigen Oberflachen
DE4493859D2 (de) Estriol enthaltendes hormonales Mittel zur Prophylaxe und Behandlung arterieller Erkrankungen beim Mann, Verfahren zu seiner Herstellung und dessen Verwendung
ATE419348T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee